Terms: = Liver cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b
118 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. SCARB1-encoded circ _0029343 induces p73 splicing to promote growth and metastasis of hepatocellular carcinoma via miR-486-5p/SRSF3 axis.
Zhu S; Cao S; Che J; Zhao L; Su Z; Li D; Pei R; Xu L; Ding Y; Zhou W
J Biochem Mol Toxicol; 2024 Feb; 38(2):e23646. PubMed ID: 38345168
[TBL] [Abstract] [Full Text] [Related]
3. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
4. GIPC1 promotes tumor growth and migration in gastric cancer via activating pdgfr/PI3K/AKT signaling.
Li T; Zhong W; Yang L; Zhao Z; Wang LI; Liu C; Li W; Lv H; Wang S; Yan J; Wu T; Song G; Luo F
Oncol Res; 2023; 32(2):361-371. PubMed ID: 38186571
[TBL] [Abstract] [Full Text] [Related]
5. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract] [Full Text] [Related]
6. Effect of Verapamil, a P-glycoprotein-1 and Cytochrome P450 3A4 Inhibitor, on Pharmacokinetics and Metabolic Stability of Ripretinib: A Drug-Drug Interaction Study in Rats.
Mudavath S; Ashok D
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):733-746. PubMed ID: 37831396
[TBL] [Abstract] [Full Text] [Related]
7. Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis.
Tian S; Hu Y; Zhang M; Wang K; Guo G; Li B; Shang Y; Han Y
Arthritis Res Ther; 2023 Oct; 25(1):186. PubMed ID: 37784152
[TBL] [Abstract] [Full Text] [Related]
8. Based on network pharmacology and experiments to explore the underlying mechanism of Mahonia bealei (Fortune) Carrière for treating alcoholic hepatocellular carcinoma.
Zhang N; Zhu Y; Zhang X; Yang K; Yang X; An M; Tian C; Li J
J Ethnopharmacol; 2024 Jan; 318(Pt A):116919. PubMed ID: 37453621
[TBL] [Abstract] [Full Text] [Related]
9. Hepatic Stellate Cell Targeting Using Peptide-Modified Biologicals.
Bansal R; Poelstra K
Methods Mol Biol; 2023; 2669():269-284. PubMed ID: 37247067
[TBL] [Abstract] [Full Text] [Related]
10. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract] [Full Text] [Related]
11. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
[TBL] [Abstract] [Full Text] [Related]
12. Yupingfeng San exhibits anticancer effect in hepatocellular carcinoma cells via the MAPK pathway revealed by HTS
Pei T; Dai Y; Tan X; Geng A; Li S; Gui Y; Hu C; An J; Yu X; Bao X; Wang D
J Ethnopharmacol; 2023 Apr; 306():116134. PubMed ID: 36627003
[TBL] [Abstract] [Full Text] [Related]
13. HS6ST1 overexpressed in cancer-associated fibroblast and inhibited cholangiocarcinoma progression.
Hu S; Xia C; Zou H; Ren W; Liu L; Wang L; Kang Q; He K; Wang T; Zhang X
Dig Liver Dis; 2023 Aug; 55(8):1114-1125. PubMed ID: 36586771
[TBL] [Abstract] [Full Text] [Related]
14. Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing pdgfrb/YAP/CCN2 Axis Activity.
Luo ZY; Tian Q; Cheng NM; Liu WH; Yang Y; Chen W; Zhang XZ; Zheng XY; Chen MS; Zhuang QY; Zhao BX; Liu CS; Liu XL; Li Q; Wang YC
Chin J Integr Med; 2024 Feb; 30(2):115-124. PubMed ID: 35947230
[TBL] [Abstract] [Full Text] [Related]
15. Adrenal Cortical Carcinoma and Additional Rare Pathologic Findings in Multi-Organs in a Birt-Hogg-Dubé Syndrome Patient: With an Emphasis on the Molecular Characteristics of Adrenal Cortical Carcinoma.
Kim D; Murvelashvili N; Hamidi O; Jia L
Int J Surg Pathol; 2023 Aug; 31(5):689-694. PubMed ID: 35946080
[TBL] [Abstract] [Full Text] [Related]
16. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract] [Full Text] [Related]
17. Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib.
Nakashima S; Sekine A; Sawa N; Kawamura Y; Kono K; Kinowaki K; Kawada M; Hasegawa E; Akuta N; Suzuki Y; Ohashi K; Takaichi K; Ubara Y; Hoshino J
Intern Med; 2022 Oct; 61(20):3083-3088. PubMed ID: 35342129
[TBL] [Abstract] [Full Text] [Related]
18. Curc-mPEG454, a PEGylated curcumin derivative, as a multi-target anti-fibrotic prodrug.
Xiao S; Deng Y; Shen N; Sun Y; Tang H; Hu P; Ren H; Peng M
Int Immunopharmacol; 2021 Dec; 101(Pt A):108166. PubMed ID: 34628270
[TBL] [Abstract] [Full Text] [Related]
19. Donafenib: First Approval.
Keam SJ; Duggan S
Drugs; 2021 Nov; 81(16):1915-1920. PubMed ID: 34591285
[TBL] [Abstract] [Full Text] [Related]
20. Establishment of a 3D model of tumor-driven angiogenesis to study the effects of anti-angiogenic drugs on pericyte recruitment.
Qiu Y; Wang N; Guo T; Liu S; Tang X; Zhong Z; Chen Q; Wu H; Li X; Wang J; Zhang S; Ou Y; Wang B; Ma K; Gu W; Cao J; Chen H; Duan Y
Biomater Sci; 2021 Sep; 9(18):6064-6085. PubMed ID: 34136892
[TBL] [Abstract] [Full Text] [Related]
[Next]
